期刊文献+

RP-HPLC法测定人血浆和尿液中美罗培南浓度 被引量:6

Determination of meropenem in humam plasma and urine by RP-HPLC
下载PDF
导出
摘要 目的建立测定人血浆和尿液中美罗培南含量的RP-HPLC法。方法血浆样品经乙腈沉淀蛋白,二氯甲烷2次提取去杂质,取水相进样;尿液稀释后直接进样。以甲硝唑为内标,色谱柱为Capcell Pak MG C18(4.6 mm×150 mm,5μm)柱,流动相为乙腈-0.02 mol/L NaH2PO4溶液(体积比10∶90),流速为1.0 mL/min,检测波长为298 nm,柱温为30℃。结果美罗培南在血浆样品和尿样中的线性范围分别为0.2~100.0μg/mL和2~1 000μg/mL,提取回收率平均值分别为80.4%和101.1%,方法回收率平均值分别为99.2%和100.3%,日内、日间RSD值均低于8.8%。结论该方法简便、灵敏、专属性强,能满足人血浆和尿液中美罗培南含量测定及药动学研究的需要。 Objective To develop a simple and rapid HPLC method for the simultaneous determination of meropenem in human plasma and urine.Methods Plasma samples were deproteinized with acetonitrile followed by extraction with dichloromethane and injection of the upper aquous phase and urine samples were diluted with mobile phase.The analysis was conducted on a Capcell Pak MG C18 column.The flow rate was 1.0 mL/min and the column temperatunre was 30 ℃.The detecting wavelengh was at 298 nm.The mobile phase consisted of acetonitrile-0.02 mol/L biphosphate sodium(10∶90).Results The linear range of meropenem in plasma and urine samples were 0.2-100.0 μg/mL and 2-1 000 μg/mL respectively.The average extraction recovery ratio in plasma and urine samples were 80.4% and 101.1%,and the average method recovery ratio in plasma and urine samples were 99.2% and 100.3%,respectively.The RSD of intra-and inter-day were both less than 8.8%.Conclusion The method is simple,rapid and accurate,which is suitable for the study of pharmacokinetics of meropenem.
出处 《广东药学院学报》 CAS 2011年第6期567-570,共4页 Academic Journal of Guangdong College of Pharmacy
关键词 美罗培南 高效液相色谱法 药动学 meropenem RP-HPLC pharmacokinetics
  • 相关文献

参考文献5

二级参考文献20

  • 1砂川洵,徐亲民.碳青霉烯类抗生素 Meropenem 的开发[J].国外医药(抗生素分册),1993,14(6):416-418. 被引量:3
  • 2[1]Kanazawa K, Nouda H, Sumita Y, et al. Structure-activity relationships of carbapenems to the antagonism of the antipseudomonal activity of other beta-lactam agents and to the beta-lactamase inducibility in Pseudomonas aeruginosa: effects of lbeta-methyl group and C-2 side chain[J]. JAntibiot Tokyo, 1999;52: 142-149.
  • 3[2]Ishikawa K, Kojima K, Miyauchi M, et al. Synthesis and structureactivity relationships of 1beta-methylcarbapenems with quaternary ammonium side chains[J]. J Antibiot Tokyo, 1998;51:757-570.
  • 4[3]Branch CL, Burton G, Clarke GJ, et al. Novel C-2 substituted carbapenem derivatives. Part IV. Synthesis and biological activity of five membered heteroaromatic derivatives[J]. J Antibiot Tokyo,1998;51:210-220.
  • 5[4]Geiss HK, Beck G. Comparative in vitro activity of meropenem versus other routinely used antimicrobials against 18632 aerobic bacteria tested in 92 German centers[J]. Int J Antimicrob Agents,1998; 10: 237-243.
  • 6[5]Bax RP, Bastain W, Featherstone A, et al. The pharmacokinetics of meropenem in volunteers[J]. J Antimicrob Chemother, 1989;24 (Suppl. A): S311-S320.
  • 7[6]Basoli A, Meli EZ, Mazzocchi P, et al. V. Imipenem/cilastatin (1.5 g daily) versus meropenem (3.0 g daily) in patients with intraabdominal infections: results of a prospective, randomized, multicentre trial[J]. Scand Infect Dis, 1997;29:503-508.
  • 8[7]Nakashima M, Uematsu T, Kanamaru M. Clinical phase I study of meropenem[J]. Chemotheropy, 1992; 40(Suppl.):S258-S275.
  • 9P faller M A, Jones R N. A review of the in vitro activity of meropenem and comparative alatimicrobial agents tested 30, 254 aerobic and anaerobic pathogens isolated world wide[J]. Diagn Microbiol Infect Dis, 1997,28(4) : 157.
  • 10Hutchison M, Faulkner K L, Turner P J, et al. A compilation of meropenem tissue distribution date[J].J Antimicrob Chemother, 1995,36 (Suppl A) : 43.

共引文献875

同被引文献43

引证文献6

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部